CONFIDENTIAL TREATMENT REQUESTED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENTConfidential Treatment Requested • October 14th, 2014 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
This DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, effective as of this 15th day of April 2014 (the “Effective Date”), between, MabVax Therapeutics, a Delaware Corporation (“Customer”), having its principal place of business at 11588 Sorrento Valley Road, Suite 20, San Diego CA 92121, and Gallus Biopharmaceuticals NJ, LLC, a Delaware limited liability company with offices at 201 College Road East, Princeton, NJ 08540 (“Gallus”). Customer and Gallus are referred to herein each as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED OPTION AGREEMENTConfidential Treatment Requested • October 14th, 2014 • Mabvax Therapeutics Holdings, Inc. • Pharmaceutical preparations • Delaware
This Option Agreement (the “Agreement”), effective as of August 29, 2014 (the “Effective Date”), is entered by and between MabVax Therapeutics, Inc., with a principal place of business at 11588 Sorrento Valley Road, Suite 20, San Diego, CA 92121 (“MabVax”), and Juno Therapeutics, Inc., with a principal place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
BEGINNING WITH THE EFFECTIVE DATE OF THIS SUPPLEMENTAL AGREEMENT, THE CONTRACT IS AMENDED AS FOLLOWS:Mabvax Therapeutics Holdings, Inc. • October 14th, 2014 • Pharmaceutical preparations
Pursuant to FAR 52.217-9, Option to Extend the Term of the Contract, the Government hereby exercises its option to fund the contract term from August 15, 2014 through August 15, 2016 (Option Period 1), this contract is hereby changed as follows:
